MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Form 10-Q — Nov 5, 2026
Maravai LifeSciences reported Q3 2026 revenue of $45.9 million, up 10.1% year over year, with nine-month revenue of $163.1 million up 20.1%. The 10-Q shows a sharp operational turnaround driven by the 2025 Corporate Realignment Plan, with Q3 gross margin jumping to 35.3% from 13.6% and quarterly Adjusted EBITDA swinging to positive $5.8 million from negative $10.8 million a year ago. Despite the improvement, Maravai still posted a Q3 net loss of $24.0 million ($13.8 million attributable to the company, or $0.09 per Class A share) and holds $73.0 million in cash against $147.2 million of long-term debt following a June 2026 refinancing into a $150 million term loan maturing in 2032.
Key figures
- Revenue
- 163130000
- Total Debt
- 147178000
- Revenue Yoy
- 20.1% (nine months); Q3 +10.1%
- Total Assets
- 600067000
- Cash Position
- 73023000
- Shares Outstanding
- 149,254,467 Class A; 110,684,080 Class B
- Goodwill
- 129429000
- Employees
- 410
- Llc ownership
- 57.4% of Topco LLC units; GTCR affiliates control ~50.3% voting power
- Q3 2026 revenue
- 45851000
- Q3 gross margin
- 35.3% vs 13.6% prior year
- Cygnus q3 revenue
- 17501000
- Term loan facility
- $150.0M, SOFR+5.00%, matures June 2, 2032
- Nine month gross margin
- 43.2% vs 15.6% prior year
- Q3 2026 adjusted ebitda
- 5820000
- Restructuring nine month
- 5764000
- Nine month adjusted ebitda
- 34821000
- Loss on debt extinguishment
- 3413000
- Goodwill impairment prior year
- 42884000
- Operating cash flow nine month
- 17672000
- Q3 cleancap prior year contributions
- none in Q3 2026; $14.3M in Q1 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.